Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment
Completed
- Conditions
- Sleep Disorder
- Registration Number
- NCT03912571
- Lead Sponsor
- NYU Langone Health
- Brief Summary
The purpose of this study is to determine the sleep patterns of subjects with or without sleep disturbances (insomnia, sleep apnea) and compare these findings with their previous FDG/PIB PET, structural MRI and brain blood flow scams performed during their participation in the Following studies 'Alzheimer's Disease Core Center (ADCC) Clinical Evaluation' (IRB: 2942), MRI Progression Markers of Cognitive Decline in the Elderly' (IRB:09-0586), or 'Imaging Neuro inflammation in Alzheimer's Disease with \[11C\] Arachidonic Acid (AA) and PET'(IRB: 10-00442).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
- All subjects will have participated in prior CBH studies and have agreed to an FDG, PIB and MRI scans.
Exclusion Criteria
- Diagnosis of sleep apnea and under treatment with a continuous positive airway pressure (CPAP) machine.
- Active depressive episode during the evaluation with a Geriatric Depression Scale score >7 and/or a Clinical Global Impression scale for depression score >4.
- Moderate Cognitive decline (GDS >3).
- Severe primary or secondary insomnia except insomnia due to SDB.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decreased cerebral blood flow (CBF) 1 Week Measured by perfusion MRI
Measure of vasoreactivity to CO2 (VRCO2) 1 Week subjects will breath through a respiratory tube and CO2 will be meaured
Increase in cortical AB plaque burden 1 Week Measured by PIB PET
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
NYU Langone Medical Center
🇺🇸New York, New York, United States
NYU Langone Medical Center🇺🇸New York, New York, United States